Menu Search
Equities

Petros Pharmaceuticals Inc

PTPI:NAQ

Petros Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.3515
  • Today's Change-0.024 / -6.32%
  • Shares traded97.31k
  • 1 Year change-79.01%
  • Beta2.3015
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Petros Pharmaceuticals Inc had relatively flat revenues (5.99m to 5.82m), though the company grew net income from a loss of 20.04m to a smaller loss of 8.16m. A reduction in the selling, general and administrative costs as a percentage of sales from 203.76% to 159.07% was a component in the net income growth despite flat revenues.
Gross margin70.21%
Net profit margin-171.23%
Operating margin-389.61%
Return on assets-26.18%
Return on equity-196.48%
Return on investment-39.25%
More ▼

Cash flow in USDView more

In 2023, Petros Pharmaceuticals Inc increased its cash reserves by 41.49%, or 3.91m. Cash Flow from Financing totalled 11.54m or 198.15% of revenues. In addition the company used 7.63m for operations while cash used for investing totalled .
Cash flow per share-2.90
Price/Cash flow per share--
Book value per share0.988
Tangible book value per share0.1769
More ▼

Balance sheet in USDView more

Petros Pharmaceuticals Inc has a Debt to Total Capital ratio of 45.39%, a lower figure than the previous year's 58.98%.
Current ratio1.40
Quick ratio1.26
Total debt/total equity0.8311
Total debt/total capital0.4539
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.